- $151.73m
- $137.59m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 11.9 | ||
| Price to Tang. Book | 11.9 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -142.1% | ||
| Return on Equity | -125.5% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.13 | 0.13 | 0.13 | 0.13 | n/a | n/a | 4.35 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 6th, 2003
- Public Since
- July 27th, 2021
- No. of Shareholders
- 118
- No. of Employees
- 42
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 29,347,468
- Address
- 117 Kendrick Street,, Suite 450, NEEDHAM, 02494
- Web
- https://www.candeltx.com/
- Phone
- +1 6179165445
- Auditors
- KPMG LLP
Upcoming Events for CADL
Similar to CADL
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
As of Today at 19:04 UTC, shares in Candel Therapeutics are trading at $5.17. This share price information is delayed by 15 minutes.
Shares in Candel Therapeutics last closed at $5.17 and the price had moved by +266.67% over the past 365 days. In terms of relative price strength the Candel Therapeutics share price has outperformed the S&P500 Index by +205.12% over the past year.
The overall consensus recommendation for Candel Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Candel Therapeutics does not currently pay a dividend.
Candel Therapeutics does not currently pay a dividend.
Candel Therapeutics does not currently pay a dividend.
To buy shares in Candel Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $5.17, shares in Candel Therapeutics had a market capitalisation of $151.73m.
Here are the trading details for Candel Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CADL
Based on an overall assessment of its quality, value and momentum Candel Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Candel Therapeutics is $11.00. That is 112.77% above the last closing price of $5.17.
Analysts covering Candel Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.91 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Candel Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +387.69%.
As of the last closing price of $5.17, shares in Candel Therapeutics were trading +246.32% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Candel Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.17.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Candel Therapeutics' management team is headed by:
- Paul Manning - CHM
- Paul Tak - PRE
- Estuardo Aguilar- Cordova - CFD
- John Canepa - CFO
- Laura Aguilar - OTH